Immix Biopharma (IMMX) Notes Payables (2020 - 2022)

Immix Biopharma has reported Notes Payables for 3 years, with the latest figure at $50000.0 in Q1 2022.

• Quarterly Notes Payables changed N/A year-over-year to $50000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $50000.0 (changed N/A YoY) and the FY2021 annual result came in at $50000.0, changed 0.0% from the prior year.
• Notes Payables held at $50000.0 in Q1 2022 per IMMX's latest filing, from $50000.0 in the prior quarter.
• Over five years, Notes Payables peaked at $50000.0 in Q4 2020 and troughed at $50000.0 in Q4 2020.
• A 3-year average of $50000.0 and a median of $50000.0 in 2020 frame the typical range for Notes Payables.
• The widest YoY moves for Notes Payables: up 0.0% in 2021, down 0.0% in 2021.
• Over 3 years, Notes Payables stood at $50000.0 in 2020, then changed by 0.0% to $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022.
• According to Business Quant data, Notes Payables over the past three periods registered $50000.0, $50000.0, and $50000.0 for Q1 2022, Q4 2021, and Q4 2020 respectively.